Last reviewed · How we verify

Allerderm — Portfolio Competitive Intelligence Brief

Allerderm pipeline: 2 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
T.R.U.E. Test T.R.U.E. Test marketed
Ethylenediamine dihydrochloride allergen patch Ethylenediamine dihydrochloride allergen patch marketed Contact allergen diagnostic agent Dermatology / Allergy & Immunology
Metal Panel T.R.U.E. Test Metal Panel T.R.U.E. Test phase 3 Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Allerderm:

Cite this brief

Drug Landscape (2026). Allerderm — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/allerderm. Accessed 2026-05-15.

Related